EUVIMEDOpdag EUVIMED
Crossref

Anticoagulation Therapy in End-of-Life Care

Ji Yun Lee

Clinical & Experimental Thrombosis and Hemostasis · 2026-05-10 · 11 (1) · 1-3

DOI: 10.14345/ceth.25005 ↗

At a glance

Journal article in Clinical & Experimental Thrombosis and Hemostasis, published online on 2026-05-10. Written by Ji Yun Lee. 29 references.

AbstractBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Anticoagulation in end-of-life patients requires complex and sensitive clinical judgments. When life expectancy is limited, clinicians must carefully balance the benefits of preventing thromboembolism against the risks of bleeding. Care at the end of life should prioritize quality of life, symptom relief, and the values of patients and their families. Clinicians should engage in thorough communication to clarify goals and limits of care, facilitate shared decision-making to determine the optimal course, and establish practical clinical support and clear evidence to guide anticoagulation management in the terminal phase.

Cite

APA

Lee, J. Y. (2026). Anticoagulation Therapy in End-of-Life Care. Clinical & Experimental Thrombosis and Hemostasis, 11(1), 1-3. https://doi.org/10.14345/ceth.25005

Vancouver

Lee JY. Anticoagulation Therapy in End-of-Life Care. Clinical & Experimental Thrombosis and Hemostasis. 2026;11(1):1-3. doi:10.14345/ceth.25005

BibTeX
@article{Lee2026,
  author = {Lee, Ji Yun},
  title = {Anticoagulation Therapy in End-of-Life Care},
  journal = {Clinical & Experimental Thrombosis and Hemostasis},
  year = {2026},
  volume = {11},
  number = {1},
  pages = {1--3},
  doi = {10.14345/ceth.25005}
}
Start for free →